

Introduction

fibrosis

Study Design

data registry

## Improved Survival After Repeat Lung Transplantation at Cystic Fibrosis Care Centers

Alexis Chidi MD PhD MSPH,<sup>1</sup> Aravind Krishnan BA,<sup>1</sup> Eric Nolley MD MS,<sup>2</sup> Sean Agbor-Enoh MD PhD,<sup>2</sup> Natalie E. West MD MHS,<sup>2</sup> Erin Tallarico, RN,<sup>4</sup> Abigail Thaxton, BA,<sup>4</sup> Jonathan B. Orens MD,<sup>2</sup> Jinny Ha MD,<sup>1</sup> Pali D. Shah MD,<sup>2</sup> Dorry Segev, MD PhD,<sup>1</sup> Allan Massey, MHS PhD,<sup>3</sup> Robert SD Higgins MD MHS, <sup>1</sup> Christian A. Merlo MD MPH, <sup>2,3</sup> Errol L. Bush MD <sup>1</sup>



**Results (Cont.)** 

**Overall Survival** 

<sup>1</sup> Division of Thoracic Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA

## Background

## Results

Characteristics of Patients Treated at CFCC vs. Non-CFCC Facilities (2005-2018)

Characteristic, N (%) Non-CFCC CFCC Improved outcomes after repeat lung Median Survival N=59 N=244 transplant in patients with cystic fibrosis & 31 (10) 31 (8) Age, m (sd) 5 allograft dysfunction Male Gender 35 (59) 116 (48) BMI, m (sd) 18 (3) 18 (3) Repeat transplantation is technically Preop Life Support 10 (17) 75 (31) challenging & requires highly specialized 3 Preop Ventilator Support 9 (15) 60 (25) Years perioperative care Preop Status 2.8 2 ICU 10 (17) 74 (30) Cystic Fibrosis Care Centers (CFCC) are Hospital (Non-ICU) 14 (24) 44 (18) accredited to provide specialized CFCC Not Hospitalized 35 (59) 125 (51) multidisciplinary care for patients with cystic 81% FEV1 (% predicted), m (sd) 23 (13) 23 (14) Ω 40 (14) FVC (% predicted), m (sd) 41 (14) CFCC Non-CFCC Transplant Type Research Question Hazard Ratio 0.65 (0.44-0.96) Single 5 (8) 15 (6) In adult patients with cystic fibrosis, is Double 54 (92) 229 (94) treatment at a Cystic Fibrosis Care Center Note: CFCC - Cystic Fibrosis Care Center, FEV1 - forced expiratory associated with improved postoperative **Summary of Key Findings** volume in 1 second, FVC- forced vital capacity, ICU - intensive outcomes after repeat lung transplantation? care unit, m - mean, sd - standard deviation Patients undergoing repeat lung Graft Survival Among Patients with CF Undergoing Repeat Lung Transplantation **Methods** transplantation at CFCCs had longer graft and 1.00 overall survival compared to those treated at non-CFCCs 0.75 Patients treated at CFCCs lived on average 1.5 Retrospective cohort study of data from the Scientific Registry of Transplant Recipients & CF years longer than those at non-CFCCs Graft Survival 0.50 Limitation: Unmeasured variables may impact **Population**: Adult patients with cystic fibrosis choice of treatment center as well as survival who underwent repeat lung transplantation outcomes from 2005-2018 0.25 Conclusion Intervention: Care at CFCC vs. non-CFCC facility Outcome measures: Graft survival (freedom 0.00 from death, graft failure, and re-Specialized care at Cystic Fibrosis Care Centers transplantation), overall survival ź 10 Ŕ may confer a survival advantage after lung 6 Years transplantation, even among high acuity patient Analysis: Multivariable Cox proportional Non-CFCC CFCC subgroups hazards model